Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–3 of 3 results
Advanced filters: Author: Colleen Annesley Clear advanced filters

  • In the final report of a phase 1 trial evaluating intracerebroventricular B7-H3-targeting CAR T cells in children and young adults with diffuse intrinsic pontine glioma, repeated intracranial infusions were feasible and well tolerated with a median overall survival of 19.8 months and 3 patients surviving over 40 months from diagnosis.

    • Nicholas A. Vitanza
    • Rebecca Ronsley
    • Michael C. Jensen
    ResearchOpen Access
    Nature Medicine
    Volume: 31, P: 861-868

  • In this Perspective, the authors and the members of the Integrated Multidisciplinary Paediatric Autoimmunity and Cell Therapy (IMPACT) working group discuss specific considerations for the use of chimeric antigen receptor (CAR) T cell therapies in paediatric patients with rheumatic diseases.

    • Holly Wobma
    • Stacy P. Ardoin
    • Melissa Tesher
    Reviews
    Nature Reviews Rheumatology
    Volume: 21, P: 494-506

  • A host of additional toxicities and/or potential late effects of chimeric antigen receptor (CAR) T cell therapy beyond cytokine release syndrome (CRS) warrant further investigation. Herein, experts in paediatric cell therapy, supportive care and/or study of late effects from cancer and haematopoietic stem cell transplantation present six key focus research areas related to CAR T cell-related outcomes beyond CRS.

    • Haneen Shalabi
    • Juliane Gust
    • Nirali N. Shah
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 18, P: 363-378